200001528-9
IPOS reference

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/14, 405/12, 417/12, A61K 31/495 — A1

(11) International Publication Number: **WO 99/29687**

(43) International Publication Date: 17 June 1999 (17.06.99)

(21) International Application Number: PCT/EP98/07771

(22) International Filing Date: 27 November 1998 (27.11.98)

(30) Priority Data:
97203808.7 5 December 1997 (05.12.97) EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: WIGERINCK, Piet, Tom, Bert, Paul [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). VERSCHUEREN, Wim, Gaston [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). SCHROVEN, Marc, Francis, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). DE BRUYN, Marc, Frans, Leopold [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B–2340 Beerse (BE).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES HAVING FUNDIC RELAXATION PROPERTIES



(I)



(A)

(c-1) (c-2) (c-3) (c-4) (c-5)

(57) Abstract

The present invention of compounds of formula (I), a stereochemically isomeric form thereof, an *N*-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk^1 is C_{1-6}alkanediyl optionally substituted with hydroxy, C_{1-4}alkyloxy or C_{1-4}alkylcarbonyloxy; $-Z^1-Z^2-$ is a bivalent radical; R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, hydroxy, halo and the like; or when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical; R^4 is hydrogen or C_{1-6}alkyl; A is a bivalent radical of formula $-NR^6-Alk^2-$(b–1), or *–N*piperidinyl–$(CH_2)_m$(b–2) wherein m is 0 or 1; R^5 is a radical of formula (A), wherein n is 1 or 2; p^1 is 0, and p^2 is 1 or 2; or p^1 is 1 or 2, and p^2 is 0; X is oxygen, sulfur or $=NR^9$; Y is oxygen or sulfur; R^7 is hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl; R^8 is C_{1-6}alkyl, C_{3-6}cycloalkyl phenyl or phenylmethyl; R^9 is cyano, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkyloxycarbonyl or aminocarbonyl; R^{10} is hydrogen or C_{1-6}alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.